A symptom combination predicting treatment -resistant schizophrenia ? A strategy for real -world clinical practice

被引:15
|
作者
Ortiz, Bruno B. [1 ,2 ]
Higuchi, Cinthia H. [1 ,2 ]
Noto, Cristiano [1 ,2 ]
Joyce, Dan W. [3 ]
Correll, Christoph U. [4 ,5 ]
Bressan, Rodrigo A. [1 ,2 ,3 ]
Gadelha, Ary [1 ,2 ]
机构
[1] Univ Fed Sao Paulo, Dept Psychiat, Interdisciplinary Lab Clin Neurosci LiNC, Rua Pedro de Toledo 669,3 Andar, BR-05039032 Sao Paulo, SP, Brazil
[2] Univ Fed Sao Paulo, Dept Psychiat, Schizophrenia Program Proesq, Sao Paulo, SP, Brazil
[3] Kings Coll London, Cognit Schizophrenia & Imaging Lab, Dept Psychosis Studies, Inst Psychiat Psychol & Neurosci, London, England
[4] Zucker Hillside Hosp, Dept Psychiat Res, Northwell Hlth, Glen Oaks, NY USA
[5] Hofstra Northwell Sch Med, Dept Psychiat & Mol Med, Hempstead, NY USA
基金
巴西圣保罗研究基金会;
关键词
NEGATIVE SYNDROME SCALE; CLOZAPINE; DISORGANIZATION; ANTIPSYCHOTICS; REMISSION; EFFICACY; PANSS;
D O I
10.1016/j.schres.2020.01.002
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Early identification of symptoms that can predict treatment-resistant schizophrenia (TRS) could help clinicians to avoid delays in clozapine therapy. This study aims to investigate symptom patterns that could predict TRS using a discovery/replication study design. First, we followed a cohort of inpatients with schizophrenia (n = 164) in which the most discriminative items at baseline of the Positive and Negative Syndrome Scale (PANSS) were determined using logistic regression with TRS status as an outcome. Using Receiver Operating Characteristic (ROC) curves, we tested the prediction performance of multiple combinations of the identified items. The same items' combination was tested in an independent replication sample of (n = 207) outpatients with schizophrenia. In the discovery sample, the best combination to predict TRS at the discharge was the sum of three baseline PANSS items – conceptual disorganization (P2), difficulty in abstract thinking (N5), and unusual thought content (G9). The P2 + N5 + G9 model yielded an area under the curve (AUC) of 0.881, a sensitivity of 77.8%, and a specificity of 83.3%. In the outpatient sample, the model P2 + N5 + G9 predictive accuracy for TRS was only in the range of “acceptable” with an AUC of 0.756 and sensitivity of 72.3% and a specificity of 74.4%. Overall, the P2 + N5 + G9 model corresponds to the construct of formal thought disorder composed of disorganized thinking, concrete thinking, and bizarre-idiosyncratic thinking. Pronounced levels of these symptoms are easily identifiable in clinical practice and may be a feasible strategy in TRS. Replicating in first-episode cohorts is desirable to understand the likely clinical utility. © 2020 Elsevier B.V.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 50 条
  • [1] TREATMENT-RESISTANT SCHIZOPHRENIA: CHALLENGES AND IMPLICATIONS FOR CLINICAL PRACTICE
    Sagud, Marina
    [J]. PSYCHIATRIA DANUBINA, 2015, 27 (03) : 319 - 326
  • [2] Management of Treatment-Resistant Depression in Real -World Clinical Practice Settings Across Asia
    Wang, Gang
    Han, Changsu
    Liu, Chia-Yih
    Chan, Sandra
    Kato, Tadafumi
    Tan, Wilson
    Zhang, Lili
    Feng, Yu
    Ng, Chee H.
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 2943 - 2959
  • [3] Combination of clozapine and ziprasidone in treatment-resistant schizophrenia - An open clinical study
    Ziegenbein, M
    Kropp, S
    Kuenzel, HE
    [J]. CLINICAL NEUROPHARMACOLOGY, 2005, 28 (05) : 220 - 224
  • [4] Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice
    Fiorillo, Andrea
    Cuomo, Alessandro
    Sampogna, Gaia
    Albert, Umberto
    Calo, Paola
    Cerveri, Giancarlo
    De Filippis, Sergio
    Masi, Gabriele
    Pompili, Maurizio
    Serafini, Gianluca
    Vita, Antonio
    Zuddas, Alessandro
    Fagiolini, Andrea
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (16) : 1801 - 1818
  • [5] Combination of clozapine and aripiprazole in treatment-resistant schizophrenia: An open clinical study
    Mitsonis, C.
    Katsa, A.
    Dimopoulos, N.
    Andriotis, N.
    Stamatopoulou, K.
    Liolios, K.
    Pagalis, N.
    Sotiropoulos, G.
    Maragoudaki, E.
    Tsakiris, F.
    Katsanou, M. N.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S266 - S266
  • [6] Predicting real-world functional milestones in schizophrenia
    Olsson, Anna-Karin
    Hjarthag, Fredrik
    Helldin, Lars
    [J]. PSYCHIATRY RESEARCH, 2016, 242 : 1 - 6
  • [7] The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study
    Jinbin Chen
    Peiyao Xiong
    Man Nie
    Yangxun Pan
    Juncheng Wang
    Dandan Hu
    Zhongguo Zhou
    Yaojun Zhang
    Minshan Chen
    Li Xu
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2491 - 2500
  • [8] The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study
    Chen, Jinbin
    Xiong, Peiyao
    Nie, Man
    Pan, Yangxun
    Wang, Juncheng
    Hu, Dandan
    Zhou, Zhongguo
    Zhang, Yaojun
    Chen, Minshan
    Xu, Li
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2491 - 2500
  • [9] The Effect of Clozapine and Another Antipsychotic Combination Treatment on the Clinical Outcomes of Treatment Resistant Schizophrenia Inpatients
    Kalter, Ehud
    Konas, Shai
    Weizman, Abraham
    [J]. BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S344 - S344
  • [10] Novel factor-based symptom scores in treatment resistant schizophrenia: Implications for clinical trials
    McMahon, RP
    Kelly, DL
    Kreyenbuhl, J
    Kirkpatrick, B
    Love, RC
    Conley, RR
    [J]. NEUROPSYCHOPHARMACOLOGY, 2002, 26 (04) : 537 - 545